New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 24, 2014
04:55 EDTSIAL, SIAL, SIAL, MMS, MMS, MMS, MD, MD, MD, MASI, MASI, MASI, LPNT, LPNT, LPNT, STE, STE, STE, XRAY, XRAY, XRAY, MRK, MRK, MRK, JNJ, JNJ, JNJCitigroup to host a conference
Global Healthcare Conference is being held in New York on February 24-26.
News For SIAL;MMS;MD;MASI;LPNT;STE;XRAY;MRK;JNJ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 28, 2015
07:05 EDTJNJMacroGenics reports MGD011 advances into clinical development
Subscribe for More Information
07:04 EDTMRKMerck narrows FY15 EPS view to $3.45-$3.55, consensus $3.45
Subscribe for More Information
07:03 EDTMRKMerck reports Q2 EPS 86c, consensus 81c
Reports Q2 revenue $9.8B, consensus $9.8B.
06:49 EDTMRKMerck to acquire cCam Biotherapeutics for $95M
Merck and cCAM Biotherapeutics announced that the companies have signed a definitive agreement under which Merck will acquire cCAM Biotherapeutics, a privately held biopharmaceutical company focused on the discovery and development of novel cancer immunotherapies. Under terms of the agreement, Merck, through a subsidiary, will acquire all outstanding stock of cCAM in exchange for an upfront payment of $95M in cash. In addition, cCAM shareholders of record are eligible to receive a total of up to $510M associated with the attainment of certain clinical development, regulatory and commercial milestones. The transaction is subject to certain closing conditions.
06:32 EDTMRKMerck's grazoprevir/elbasvir application accepted by FDA
Subscribe for More Information
July 27, 2015
15:03 EDTMRKNotable companies reporting before tomorrow's open
Subscribe for More Information
14:43 EDTMRKEarnings Watch: Merck's Keytruda sales will be focus in Q2 results
Subscribe for More Information
10:40 EDTJNJLeerink major pharma analyst holds an analyst/industry conference call
Subscribe for More Information
08:32 EDTMRKMerck receives 'positive' CHMP opinion for Zerbaxa
Subscribe for More Information
07:37 EDTMRKAeterna Zentaris starts promoting Saizen for injection in 25 U.S. territories
Subscribe for More Information
July 23, 2015
17:51 EDTJNJJanssen submits sNDA to update label for Olysio
Subscribe for More Information
11:04 EDTMRKMerck announces EMA acceptance of MAA for grazoprevir/elbasvir
Subscribe for More Information
07:26 EDTSIALSigma-Aldrich's two St. Louis facilities receive ISO 13485 certification
Sigma-Aldrich has received ISO 13485 certification for expanded quality assurance capabilities at its Dekalb and Barton facilities located in St. Louis. The certification extends Sigma-Aldrich's ability to manufacture and offer critical raw materials, such as enzymes, proteins and antibodies used in diagnostic assays.
July 22, 2015
10:15 EDTJNJThoratec downgraded to Market Perform from Outperform at Northland
Subscribe for More Information
07:21 EDTSIALThe Protein Society to hold a symposium
Subscribe for More Information
07:04 EDTMRKMerck's Keytruda approved by EU for treatment of advanced melanoma in adults
Merck announced that the European Commission has approved KEYTRUDA, the company’s anti-PD-1 therapy, for the treatment of advanced melanoma in adults. The European Commission approval of pembrolizumab is based on data from three clinical studies conducted in more than 1,500 first-line and previously-treated patients with advanced melanoma. Pembrolizumab received European Commission regulatory approval based on Phase 3 data which showed it is the first and only anti-PD-1 therapy to provide a statistically superior survival benefit as a monotherapy compared to ipilimumab, the current standard of care for advanced melanoma. Today’s approval allows marketing of pembrolizumab in all 28 EU member states at the approved dose of 2 mg/kg every three weeks. The European Commission’s approval is based on data from three studies -- KEYNOTE-001, KEYNOTE-002 and KEYNOTE-006. These studies evaluated the efficacy and safety of pembrolizumab in advanced melanoma patients – across treatment lines, prognostic factors, tumor characteristics, and BRAF mutational status – and established 2 mg/kg every three weeks as the approved dose.
06:05 EDTMRKMerck, Ablynx expand immuno-oncology collaboration
Subscribe for More Information
July 21, 2015
09:03 EDTMASIMasimo sees Q2 EPS 35c-36c, consensus 30c
Subscribe for More Information
July 16, 2015
10:00 EDTMASIOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
07:42 EDTMASIMasimo downgraded to Neutral from Buy at BTIG
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use